Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409861 | 0.92 | PLA2G1B (0.39) | PLA2G1BPLA2G2AALDH1A1CYP1A2MAPK1 | |
| SCHEMBL13652974 | 0.89 | OPRM1 (0.37) | PLA2G1BPLA2G2AALDH1A1CYP1A2MAPK1 | |
| SCHEMBL12039787 | 0.89 | OPRM1 (0.37) | PLA2G1BPLA2G2AALDH1A1CYP1A2MAPK1 | |
| SCHEMBL436979 | 0.86 | PLA2G1B (0.39) | PLA2G1BPLA2G2AALDH1A1CYP1A2MAPK1 | |
| SCHEMBL21155222 | 0.85 | PLA2G1B (0.42) | PLA2G1BPLA2G2AOPRM1KCNH2HTR2A | |
| SCHEMBL23192226 | 0.83 | PLA2G1B (0.50) | PLA2G1BPLA2G2AOPRM1KCNH2HTR2A | |
| SCHEMBL20076527 | 0.81 | CYP1A2 (0.39) | PLA2G1BPLA2G2AALDH1A1CYP1A2MAPK1 | |
| SCHEMBL9289906 | 0.81 | CYP1A2 (0.44) | PLA2G1BPLA2G2ACYP1A2MAPK1KCNH2 | |
| SCHEMBL22301300 | 0.80 | PLA2G1B (0.38) | PLA2G1BPLA2G2AALDH1A1MAPK1OPRM1 | |
| SCHEMBL22487817 | 0.80 | PLA2G1B (0.33) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023141576-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022135432-A1 | MACROCYCLIC HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS, AND USE THEREOF | 南京圣和药业股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | PLA2G1B 4849/4885PLA2G2A 4875/4885ALDH1A1 81/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | PLA2G1B 4849/4885PLA2G2A 4875/4885ALDH1A1 81/4885 |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | PLA2G1B 4256/4885PLA2G2A 4179/4885ALDH1A1 237/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | PLA2G1B 3582/4885PLA2G2A 3077/4885ALDH1A1 1093/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | PLA2G1B 3582/4885PLA2G2A 3077/4885ALDH1A1 1093/4885 |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | LDLR, LIPC, SREBF2 | PLA2G1B 541/4885PLA2G2A 1250/4885ALDH1A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.